To request pricing for high-throughput use, please complete this short form.

To request pricing for portable on-site testing using our Franklin™ thermocyclers, please complete this short form.

The Biomeme SARS-CoV-2 Test Kit Only can be used to detect the RNA of severe acute respiratory syndrome coronavirus 2 that causes coronavirus disease 2019 (COVID-19), also known as "2019-nCoV" or "Wuhan coronavirus." Two RNA targets for the novel coronavirus are multiplexed together with Biomeme's process control assay for RNA extraction and RT-PCR (MS2). Assay targets include:

• SARS-CoV-2-Orf1ab gene
• SARS-CoV-2-Spike gene
• RNA Process Control (RNA extraction and RT-PCR control utilizing MS2 bacteriophage)

Our Test Kits come in 2 different form factors for you to choose from:

• Go-Strips (96 rxns per order)
• Bulk Vials (~130 rxns per order)

All Test Kits include everything you would need to test for SARS-CoV-2 with the exception of sample collection accessories, a thermocycler, and software (see our Starter Kits should you also require these items):

• Sample Prep Tray
• 200uL Exact Volume Transfer Pipettes
• M1 Sample Prep Cartridge Kit for RNA 2.0
• Fixed Volume Pipette (10 or 20 µL)
• Boxes of Pipette Tips

In addition to the kit components above, Go-Strip Test Kits include:

• SARS-CoV-2 Go-Strips (enough for 96 rxns) w/ Void Filling Caps
• Biomeme's RNA Process Control (RPC)

Whereas, Bulk Vial Test Kits include:

• SARS-CoV-2 Bulk Vials (enough for ~130 rxns)
• DNase/RNase Free Molecular Grade Water
• 1 mL Transfer Pipettes
• Empty Go-Strips w/ Void Filling Caps
• Biomeme's RNA Process Control (RPC)

If all you need are tests, check out our SARS-CoV-2 Tests only.

EUA Disclaimers

• This test has not been FDA cleared or approved;
• This test has been authorized by FDA under an EUA for use by authorized laboratories;
• This test has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens; and
• This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.